Pyrazolo[1,5-a]pyridine derivatives for treating TRPM3-mediated disorders
JP2025518047A5Pending Publication Date: 2026-05-29KATHOLIEKE UNIV LEUVEN +1
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- KATHOLIEKE UNIV LEUVEN
- Filing Date
- 2023-05-25
- Publication Date
- 2026-05-29
AI Technical Summary
Technical Problem
Current treatments for TRPM3-mediated disorders, such as pain, inflammatory hypersensitivity, and epilepsy, lack effective and side-effect-free therapies with optimal pharmacokinetic and pharmacodynamic properties.
Method used
Development of pyrazolo[1,5-a]pyridine derivatives that act as antagonists of TRPM3, offering a new class of compounds for the prevention and treatment of TRPM3-mediated disorders.
Benefits of technology
The pyrazolo[1,5-a]pyridine derivatives effectively modulate TRPM3-mediated disorders, providing potential therapeutic benefits for pain, inflammatory hypersensitivity, and epilepsy with improved safety and efficacy profiles.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2023230542000001 
Figure 2023230542000002 
Figure 2023230542000003
Abstract
The present invention relates to a compound useful for the prevention or treatment of a TRPM3-mediated disorder, more specifically a disorder selected from pain and inflammatory hypersensitivity. The present invention also relates to a method for the prevention or treatment of such TRPM3-mediated disorders.
Need to check novelty before this filing date? Find Prior Art